PM379. Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics

Objective: Many evidences suggested that impairment of glutathione-dependent system is observed in the brain of schizophrenic patients. GSH is an important substrate of glutathione peroxidase (GPx). It is recognized that selenium-dependent GPx (GPx-1) out of GPx isozymes provides a first line of defense against peroxides. Thus, we investigated in the present study a role of GPx-1 gene in schizophrenia-like psychosis induced by phencyclidine (PCP) in mice. Method: GPx-1 knock-out (KO)-, wild-type (WT)-, GPx-1 overexpressing transgenic (Tg)and non-Tg-mice were received PCP (10 mg/kg/day, s.c.) for consecutive 14 days. Novel object recognition-, forced swimming-, and social interaction-tests were performed 7 days after withdrawal from PCP. Behavioral sensitization to an acute challenge of PCP (3 mg/kg, s.c.) was also evaluated. We examined Nrf-2-dependent GSH-synthetic process in the prefrontal cortex and hippocampus. Result: PCP-induced behavioral side effects were more pronounced in the GPx-1 KO than those in WT mice, and they were less pronounced in GPx-1 Tg than those in non-Tg mice. Moreover, PCP treatment significantly reduced GSH level, and increased oxidative burdens in prefrontal cortex as compared to those in hippocampus. Treatment with PCP resulted in a significant increase in nuclear translocation of Nrf2, Nrf2 DNA binding activity, and γ-glutamylcysteine modifier subunit (GCLm) mRNA expression in WT or non-Tg mice. These inductions were not observed in GPx1 KO mice. Further, this Nrf-2 dependent GSH synthetic system was more pronounced in GPx-1 Tg than non-Tg mice. Conclusion: Our results suggest that GPx-1 gene is a potential protective factor in response to schizophrenia-like psychosis induced by PCP in mice [This study was supported by a grant (14182MFDS979) from the Korea Food and Drug Administration, Republic of Korea]. PM378 A reduced risk of severe hepatic outcome with paliperidone exposure in schizophrenia patients with viral hepatitis: a population-based retrospective cohort study Running title: Schizophrenia, severe hepatic outcome, and paliperidone Chun-Hung Chang,1,2,3 Shaw-Ji Chen,4,5,6 Chieh-Yu Liu7, Hsien-Yuan Lane1,2 * 1Department of Psychiatry, China Medical University Hospital, Taichung, Taiwan, R.O.C. 2Institute of Clinical Medicine, China Medical University, Taichung, Taiwan, R.O.C.; 3Sunshine Psychiatric Hospital, Taichung, Taiwan, R.O.C. 4Department of Psychiatry, Mackay Memorial Hospital Taitung Branch, Taitung, R.O.C. 5Mackay Junior College of Medicine, Nursing, and Management, Taipei, R.O.C. 6Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan, R.O.C. 7Biostatistical Consulting Lab, Institute of Nursing-Midwifery, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan, R.O.C. *Corresponding author: Hsien-Yuan Lane, Ph.D. 2, Yuh-Der Rd, Taichung 40447, Taiwan Institute of Clinical Medicine, China Medical University Tel: +886-422052121 extension 1073 Fax: +886-4-26202946 E-mail: chang763@ gmail.com E-mail: [email protected] Financial Disclosure: The authors have indicated they have no relevant financial relationships to disclose for this article. Conflicts of Interest: The authors declare that there is no conflict of